Principal Securities, Inc. Xenon Pharmaceuticals Inc. Transaction History
Principal Securities, Inc.
- $4.44 Trillion
- Q4 2024
A detailed history of Principal Securities, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 58 shares of XENE stock, worth $2,114. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58
Previous 45
28.89%
Holding current value
$2,114
Previous $1.77 Million
28.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XENE
# of Institutions
218Shares Held
66.7MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$207 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$165 Million1.73% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$106 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$104 Million0.06% of portfolio
-
Commodore Capital LP New York, NY2.74MShares$99.9 Million10.76% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.27B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...